[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"autism-disorder\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:autism-disorder":31},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,15,0,[8,102,128,157,185,211,239,272,294,322,351,383,411,433,464],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":27,"conditions":28,"keywords":73,"overallStatus":89,"whyStopped":4,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":101},"100641475","qaiax-aihealth4u---ai-public-health-central-microcity-a-re-quantum-ai-agency-aka-ai-city-hall-project-upsto-app-nos-64074526-64063557-63903181-63729428-100641475",false,"NCT07661823","QAIAx (AIhealth4U) - AI Public Health Central: Microcity-A (re Quantum AI Agency Aka AI City Hall Project, UPSTO App Nos. 64\u002F074,526, 64\u002F063,557, 63\u002F903,181, 63\u002F729,428","QAIAx (AIhealth4U) - AI Public Health Central: Microcity-A (re Quantum AI Agency Aka AI City Hall Project, UPSTO App Nos. 64\u002F074,526, 64\u002F063,557, 63\u002F903,181, 63\u002F729,428: A Quantum AI Public Health Agency That Provides Free Public Health Services to Registered and Sponsored Visitors\u002FOccupants for RDT&E Under 28 U.S. Code 1498 (Classified as a PPA Under 10 U.S. Code 129a)","QAIAx","Inclusion Criteria:\n\n* Individuals aged 17 to 99 years old.\n* Referral by a licensed health services professional (e.g., R.N., N.P., Ph.D., M.D.).\n* Referral by a non-profit organization (e.g., 501c3, university, church).\n* Referral by a public agency (e.g., case manager, social worker, parole\u002Fprobation\u002FPTS officer, judge).\n\nExclusion Criteria:\n\n\\* Individuals under 17 or over 99 years of age.",true,"ALL","17 Years","99 Years",{"count":22,"type":23},1000000,"ESTIMATED","INTERVENTIONAL",[26],"NA","BRIEF SUMMARY\n\nA. \"What is the purpose of this study?\"\n\nThis study will test whether the \"AI City Hall Project\" (QAIAx), a quantum artificial intelligence (AI) public health agency, can provide free or low-cost behavioral and mental health services inside self-contained, dome-enclosed communities called \"Microcities\". Researchers want to see if AI-managed public administration, AI humanoid robots, holoportation of human-figures via 'holo-suites' (e.g., AI-119 Kikkeri Holo-Suit; AI-119 Vulcan QM-Ware) and advanced AI mental-health tools can lower housing and care costs, improve mental health outcomes (e.g., particular ecosystems using AI tools among persons with one or more addiction disorders), and be financially sustainable for people on fixed incomes or public assistance.\n\nB. \"What conditions does the study focus on?\"\n\nThe study focuses on adults with:\n\n* Autism spectrum disorders (Asperger's, autism, ADHD, ASD)\n* Substance use disorders (alcohol, opioids, marijuana, cocaine, MDMA\u002Fecstasy, tobacco\u002Fnicotine)\n* Psychiatric conditions (personality disorders, narcissism, gender dysphoria, eating disorders)\n* Behavioral addictions (gambling, sex addiction) and related issues (sex offence history).\n\nC. \"What does the study involve?\"\n\nEligible volunteers live in an omni AI-managed Microcity for up to 24 months. The community is housed in a geodesic dome that contains all daily necessities: housing, food, utilities, healthcare, and public services. Daily life is managed by an AI system (ISAC) and AI humanoid robots, with only occasional human oversight. Participants receive free mental-health treatment that may include AI-driven counselling, virtual-reality therapy (holo-suits), and non-invasive digital \"attitude inoculation\" protocols designed to reduce stress and addiction cravings. All participants also take AI-technology courses as a condition of enrolment. The study does not use any FDA-regulated drug, device, or biologic.\n\n\\*\\*Who can participate?\\*\\*\n\nYou may be able to join if you:\n\n* Are an adult (18 years or older)\n* Have a diagnosis of one of the listed mental-health or addiction disorders\n* Are referred by a licensed health professional (e.g., RN, NP, PhD, MD), a non-profit organisation (e.g., 501(c)(3), university, church), or a public agency (e.g., case manager, social worker, parole\u002Fprobation officer, judge)\n* Are willing to live in a closed, AI-managed community for up to one year and complete AI educational courses.\n\nParticipants who are veterans, receive public assistance (e.g., VA disability, SSDI\u002FSSI, Medicaid, Medicare), or are experiencing homelessness may be prioritised.\n\n\\*\\*Where is the study taking place?\\*\\* The study will be conducted at Microcity sites in the United States and internationally. The first administrative site is in Richmond, Virginia, USA. Additional sites are planned in partner nations, including tribal lands, military installations, and special economic zones.\n\n\\*\\*Who is sponsoring the study?\\*\\* The study is sponsored by \\*\\*Veterans Recovery Network Inc.\\*\\*, a non-profit organization, in collaboration with \\*\\*AI-119 Vulcan Project Research \\& Educational Technology Co. (PRETCO)\\*\\* and an AI legal agency. The study is conducted under U.S. federal research and development authorities (28 U.S.C. §1498; 10 U.S.C. §129a) and is part of a Cooperative Research and Development Agreement (CRADA) with U.S. Special Operations Command (USSOCOM).\n\nThis summary describes a planned clinical study. Not all details may be final. Information may change as the study progresses.",[29,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44,45,46,47,48,49,50,51,52,53,54,55,56,57,58,59,60,61,62,63,64,65,66,67,68,69,70,71,72],"Asperger's Disorder","Asperger Disorder","Autism Disorder","Autism","ADHD - Attention Deficit Disorder With Hyperactivity","ADHD","ASD","Alcohol Abuse\u002FDependence","Alcohol Addiction","Alcohol and Other Drug Use Disorders","Alcohol and Other Substance Use Prevention","Gambling Addiction","Gambling Disorder","Sex Abuse","Sex Behavior","Sex Crimes","Sex Disorder","Sex Disorders","Gender Dysphoria, Adult","Eating Behavior Disorders","Narcotic-Related Disorders","Narcotic Addiction","Narcissism","Psychiatric Disorder","Psychedelic Effects in Healthy Volunteers","Psychedelic Experiences","Psychedelic Drug Dependence","Marijuana Use Disorder","Marijuana Abuse and Dependence","Smoking (Tobacco) Addiction","Smoking Among Youth","Smoking Abstinence","Abstinence, Sex","Opiate Substitution Treatment","Opioid Abuse (Disorder)","Opioid Abuse and Addiction","Cocaine Abuse","MDMA ('Ecstasy')","Addiction Disorders","Homeless and Low Incomes People, Refugees","Homelessness","Reliability and Validity","Anger Problems","Child Abuse, Sexual",[74,75,76,77,78,79,80,81,82,83,84,85,86,87,88],"ai city hall project","ai 119","ai119","qaia","qaiax","ai wat","veterans recovery network","veterans","addiction disorder","vulcan","artificial intelligence","agi","military","sex addiction","mental health treatment","NOT_YET_RECRUITING","2026-06-16",{"date":92,"type":93},"2026-06-22","ACTUAL",{"date":95,"type":23},"2026-08-01",{"date":97,"type":23},"2028-12-31",{"name":99,"class":100},"Veterans Recovery Network Inc.","OTHER",1,{"id":103,"slug":104,"hasResults":11,"nctId":105,"briefTitle":106,"officialTitle":106,"acronym":4,"eligibilityCriteria":107,"healthyVolunteers":17,"sex":18,"minAge":108,"maxAge":109,"enrollmentInfo":110,"targetDuration":4,"studyType":112,"phases":4,"briefSummary":113,"conditions":114,"keywords":115,"overallStatus":89,"whyStopped":4,"lastUpdateSubmitDate":119,"lastUpdatePostDateStruct":120,"startDateStruct":122,"completionDateStruct":124,"leadSponsor":126,"locationsCount":4},"100643175","achilles-tendon-and-ankle-characterization-in-adults-with-autism-100643175","NCT07634965","Achilles Tendon and Ankle Characterization in Adults With Autism","Inclusion Criteria:\n\n* a diagnosis of ASD, or with another diagnosis that includes features of ASD (such as fragile x),\n* independent in daily activities,\n* live alone,\n* have a moderate-high level of functioning.\n* Ability to understand basic instructions for performing the tests, signing an informed consent form or having a guardian sign an informed consent form\n\nExclusion criteria:\n\n* other neurological diseases (e.g., CP, multiple sclerosis),\n* significant orthopedic injuries to the lower limb in the past year,\n* previous ankle or Achilles tendon surgeries,\n* additional diseases that may affect the structure of the Achilles tendon and ankle,\n* who have not signed an informed consent form or are not interested in participating in the study","18 Years","40 Years",{"count":111,"type":23},80,"OBSERVATIONAL","This study aims to identify ankle structural and functional profiles associated with sensory responsiveness and toe walking in adults with ASD. Expected outcomes include detecting group differences between adults with ASD and matched controls and identifying associations among sensory responsiveness, toe-walking status, and objective ankle measures.",[31],[116,35,117,118],"ankle","screening","Achilles tendon","2026-06-09",{"date":121,"type":93},"2026-06-11",{"date":123,"type":23},"2026-08-10",{"date":125,"type":23},"2027-08-01",{"name":127,"class":100},"University of Haifa",{"id":129,"slug":130,"hasResults":11,"nctId":131,"briefTitle":132,"officialTitle":133,"acronym":134,"eligibilityCriteria":135,"healthyVolunteers":17,"sex":18,"minAge":136,"maxAge":4,"enrollmentInfo":137,"targetDuration":4,"studyType":24,"phases":139,"briefSummary":140,"conditions":141,"keywords":142,"overallStatus":89,"whyStopped":4,"lastUpdateSubmitDate":148,"lastUpdatePostDateStruct":149,"startDateStruct":151,"completionDateStruct":152,"leadSponsor":154,"locationsCount":101},"100616869","genes-and-autism---induced-pluripotent-stem-cells-100616869","NCT07311213","GENES AND AUTISM - Induced Pluripotent Stem Cells","EXPLORATIONS CELLULAIRES - CELLULES PLURIPOTENTES INDUITES DES SUJETS PRESENTANT UN TSA, DE LEURS APPARENTES, ET DE TEMOINS","IPSC","Inclusion Criteria:\n\n● For all participants :\n\n* 1\\) Be Included in the \"Genes and Autism\" protocol (C07-33 or C16-89).\n* 2\\) Affiliated to the social insurance, Universal Health Coverage or any equivalent system.\n\n  →As a Reminder : C07-33 inclusion criteria\n\n  ● Participants with ASD.\n* 1\\) Autistic patients must meet the diagnostic criteria of DSM-IV \\[American Psychiatric Association, 1994\\] and the criteria of ADI-R (Autism Diagnostic Interview-Revised, Lord et al., 1994) and ADOS for autism.\n\n..Or.. Patients with Asperger's syndrome must meet the DSM-IV criteria as well as the ASDI criteria for Asperger's syndrome (Asperger Syndrome Diagnostic Interview, Gillberg et al., 2001) and the ADOS for autism spectrum disorders.\n\n..Or.. Patients with ASD must meet diagnostic criteria of DSM-IV and ADOS criteria for autism spectrum disorders\n\n* 2\\) Be at least 2 years old, with no upper age limit\n* 3\\) Somatic state compatible with blood test\n\n  ● Adult controls and adult relatives of controls\n* 1\\) Be between 18 and 65 years old\n* 2\\) Somatic and intellectual state compatible with blood test\n\n  ● Controls with mental retardation\n* 1\\) Minimum age of 2 yearsIQ \\\u003C 70Child controls\n* 2\\) Minimum age of 2 years\n\n  →As a Reminder : inclusion criteria C16-89\n\n  ● Probands with ASD\n* 1\\) Meet the diagnostic criteria for ASD of the of DSM-5 \\[American Psychiatric Association, 2012\\]. The diagnosis will be based on a consensus between the clinical expertise of expert clinicians, the scores of the Autism Diagnostic Interview-Revised (ADI-R) (Lord et al, 2003) and those of the Autism Diagnosis Observational Scale (ADOS-2) (Lord et al, 1994)\n* 2\\) Be at least 24 months old with no upper age limit\n* 3\\) Somatic state compatible with a blood test\n* 4\\) Affiliation to the Social Insurance\n* 5\\) Signature of informed consent by the applicant or by the holders of parental authority if the subject is a minor or by the guardian if the subject is under guardianship\n\n  ● Controls wihout ASD\n* 1\\) At least 24 months old\n* 2\\) Somatic and Intellectual state compatible with a blood test\n* 3\\) Affiliation in the Social Insurance\n* 4\\) Signature of informed consent by the subject or by holders of parental authority if the subject is a minor, or by the guardian if the subject is under guardianship\n\n  ● Relatives of the probands with ASD or of controls without ASD\n* 1\\) At least 24 months old\n* 2\\) Somatic and intellectual state compatible with blood test\n* 3\\) Affiliation to the Social Insurance\n* 4\\) Signature of informed consent by the subject or by the holders of parental authority if the subject is a minor or by the guardian if the subject is under guardianship\n\nExclusion Criteria:\n\n* For all participants\n\n  * 1\\) Refusal to have a blood test\n  * 2\\) Medical illness (including psychiatric disorder) not yet fully stabilised and making participation in the study impossible\n  * 3\\) Person subject to a mesure of lagal protection\n  * 4\\) Known serology : VIH+ or VBH+ or VCH+\n\n    * As a reminder : exclusion criteria C07-33\n  * 1\\) For all participants : Severe Intelectual Deficiency (IQ,35 or developmental age \\\u003C18 months)\n  * 2\\) Controls : Neurological or psychiatric history other than mental retardation\n\n    o Psychiatric history, except for mental retardation, assessed using the DIGS (Diagnostic Interview for Genetic Studies, Nurnberger et al., 1994) for adults or the Kiddie-SADS (Kiddie Schedule for Affective Disorders and Schizophrenia for School-Age Children, Orvaschel et al., 1982)\n\n    o History of epileptic episodes\n\n    o Immunosuppressive treatment or known immunoinflammatory disease\n\n    →As a reminder : exclusion criteria C16-89\n  * 1\\) Probands with Autism Spectrum Disorder\n\n    o Severe intellectual disability (IQ\\\u003C35 or developmental age \\\u003C18 months)\n  * 2\\) Controls (neurotypical development)\n\n    o Identified intellectual disorder or cognitive developmental disorder\n    * Personal psychiatric history of schizophrenia, bipolar disorder, substance use disorders (except tobacco), recurrent depression (\\>2 episodes, lifetime), severe unstabilized anxiety disorder\n    * History of epilepsy episodes or severe neurological disease\n  * 3\\) Relatives of the TSA applicants or controls\n\n    * Medical condition (psychiatric or somatic) not compatible with inclusion","2 Years",{"count":138,"type":23},450,[26],"Autism spectrum disorder (ASD) is a neurodevelopmental disorder characterized by deficits in social interaction and verbal and non-verbal communication (DSM-5, 2013), affecting approximately 2% of the general population. In 5 to 40% of cases, genetic factors are identified as the cause of these disorders, with prevalence depending on the technique used (exomes and\u002For SNP arrays) and the associated intellectual deficit. In the majority of cases, the etiology remains unknown. Studies of microdeletions\u002Fmicroduplications (copy number variants) or Whole Exome Sequencing and Whole Genome Sequencing (Single Nucleotide Variants) show the involvement of numerous genes in the predisposition to autism. ASD remains a genetically heterogeneous disorder, as more than 250 genes have been associated with ASD to date.\n\nThe main objective of the project is to continue identifying genetic factors, and also to understand the biological mechanisms involved in the emergence of autistic symptoms.\n\nIdentifying biological pathways is an essential step in developing new therapeutic strategies. In addition, one of the major challenges of this study is to better understand the phenotype\u002Fgenotype relationships in ASD. This requires in-depth knowledge of the phenotypic characteristics of participants with ASD and their families, as well as neurotypical populations. This study combines the scientific expertise of researchers specializing in molecular biology, phenotypic exploration (clinical, cognitive, MRI, EEG, biochemistry, immunology), and the use of pre-therapeutic cellular models (iPSCs, neural precursors, organoids).\n\nThe objective of this work is the identification of numerous genes associated with ASD and involved in synaptic formation and regulation: NLGN3-4, SHANK1 and SHANK3, CNTN-6, and CNTNAP4. This work was combined with in-depth phenotypic explorations of ASD participants and their relatives. It has made it possible to clarify the neuroanatomical characteristics of participants with ASD and their genetic substrate, as well as the underlying cognitive processes.\n\nAll of this work opens up new prospects for identifying new therapeutic targets using preclinical cell models (IPSCs Induced pluripotent stem cells, neural progenitors, organoids) developed in particular by I-Stem and Human Technopole.",[31,35],[143,144,145,146,147],"autism","genes","phenotype","complex heritability","Induced pluripotent stem cells","2026-06-03",{"date":150,"type":93},"2026-06-05",{"date":95,"type":23},{"date":153,"type":23},"2041-08-01",{"name":155,"class":156},"Institut National de la Santé Et de la Recherche Médicale, France","OTHER_GOV",{"id":158,"slug":159,"hasResults":11,"nctId":160,"briefTitle":161,"officialTitle":162,"acronym":163,"eligibilityCriteria":164,"healthyVolunteers":11,"sex":18,"minAge":108,"maxAge":165,"enrollmentInfo":166,"targetDuration":4,"studyType":24,"phases":168,"briefSummary":169,"conditions":170,"keywords":172,"overallStatus":175,"whyStopped":4,"lastUpdateSubmitDate":176,"lastUpdatePostDateStruct":177,"startDateStruct":179,"completionDateStruct":181,"leadSponsor":183,"locationsCount":101},"100624166","piloting-the-competence-in-romance-and-understanding-sexual-health-curriculum-100624166","NCT07406100","Piloting the Competence in Romance and Understanding Sexual Health Curriculum","A Pilot Investigation of the Competence in Romance and Understanding Sexual Health Curriculum","CRUSH","Inclusion Criteria:\n\n* 18;0 to 30;11 years old;\n* Either documentation of a prior diagnosis of autism spectrum disorder or receipt of services based on an autism spectrum diagnosis OR self identification as being autistic \u002F on the autism spectrum and meeting the clinical cut-off on either the Autism Diagnostic Observation Schedule or the Autism Spectrum Quotient;\n* Ability to provide consent for the protocol and understand task demands. The Wechsler Abbreviated Scale of Intelligence, Second Edition (WASI-2) may be used to confirm cognitive level. In prior work, adults with full scale IQ of 70 or above on the WASI-2 typically meet this criterion, but a licensed clinician will review individuals who fall below an IQ of 70 on an individual basis to determine eligibility;\n* Fluent in English.\n\nExclusion Criteria:\n\n* Non-English-speaking participants (less than 50% of speech in English);\n* Known genetic etiology of ASD (e.g., Fragile X);\n* Major mental illness (e.g., bipolar disorder, schizophrenia, or psychosis);\n* Medical conditions that impact sexual function (e.g., pituitary tumor);\n* Significant sensory, motor, or physical conditions that would prevent valid participation in assessments or intervention;\n* Live more than 50 miles from the site in Brookline, MA where intervention and assessment sessions will be offered.\n* Receipt of other sexual health\u002Fdating curricula as an adult.","30 Years",{"count":167,"type":23},40,[26],"The goal of this clinical trial is to learn whether the CRUSH curriculum is possible (feasible), whether it fits the needs of the adults it is designed for (acceptable), and shows initial signs of being helpful (efficacious). CRUSH is a group-based behavioral intervention plus 1-1 coaching designed to provide sexual education and improve the skills of autistic adults for intimate relationships.\n\nThe main goals of the project are to:\n\n* Evaluate the feasibility and acceptability of the CRUSH curriculum in the context of a clinical trial with a waitlist control condition.\n* Initial exploration of how the CRUSH curriculum works and whether it is helpful.\n\nParticipants will complete:\n\n* A screening call.\n* Confirmation of clinical characteristics (autism features, language ability, cognitive ability).\n* 3 visits to assess knowledge and behaviors related to dating and sexual health at each point throughout the training curriculum (before beginning, midway, and after finishing).\n* 20 sessions of the CRUSH curriculum plus 1-1 coaching sessions. After each session, provide feedback about the session.",[32,31,171],"Autism Spectrum Disorder",[173,174],"sexual health","romantic relationships","RECRUITING","2026-04-21",{"date":178,"type":93},"2026-04-24",{"date":180,"type":93},"2026-04-01",{"date":182,"type":23},"2027-07-31",{"name":184,"class":100},"Boston Children's Hospital",{"id":186,"slug":187,"hasResults":11,"nctId":188,"briefTitle":189,"officialTitle":189,"acronym":190,"eligibilityCriteria":191,"healthyVolunteers":17,"sex":18,"minAge":192,"maxAge":193,"enrollmentInfo":194,"targetDuration":196,"studyType":112,"phases":4,"briefSummary":197,"conditions":198,"keywords":200,"overallStatus":89,"whyStopped":4,"lastUpdateSubmitDate":203,"lastUpdatePostDateStruct":204,"startDateStruct":206,"completionDateStruct":207,"leadSponsor":209,"locationsCount":101},"100632145","research-on-the-molecular-mechanism-of-cognitive-differences-between-williams-syndrome-and-autism-spectrum-disorder-100632145","NCT07509879","Research on the Molecular Mechanism of Cognitive Differences Between Williams Syndrome and Autism Spectrum Disorder","WS and ASD","Participants for Williams Syndrome Study\n\nInclusion criteria must all be met:\n\n1. Age 3-12 years old.\n2. Clinically diagnosed and confirmed by fluorescence in situ hybridization (FISH) test, with a typical microdeletion of approximately 1.55 Mb in the chromosome 7q11.23 region.\n3. Their legal guardians fully understand the study content and voluntarily sign the informed consent form, agreeing for the study participants to undergo blood sampling and genetic testing.\n\nParticipants for Autism Spectrum Disorder Study\n\nInclusion criteria must all be met:\n\n1. Age 3-12 years old.\n2. Clinically diagnosed according to the second edition of the Autism Diagnostic Observation Schedule (ADOS-2) criteria.\n3. Their legal guardians fully understand the study content and voluntarily sign the informed consent form, agreeing for the study participants to undergo blood sampling and genetic testing.\n\nParticipants for Healthy Children Study\n\nInclusion criteria must all be met:\n\n1. Age 3-12 years old, with gender as close as possible to the participants in the above two groups.\n2. No history of neurodevelopmental disorders, mental illnesses or major neurological diseases.\n3. Their legal guardians fully understand the study content and voluntarily sign the informed consent form, agreeing for the study participants to undergo blood sampling and genetic testing.\n\nCommon Exclusion Criteria for All Study Participants\n\nAny of the following conditions must be met to be excluded from the study:\n\n1. Specific medical conditions:\n2. For the Williams Syndrome group: Known or suspected presence of other pathogenic gene mutations\u002Fsyndromes other than the 7q11.23 microdeletion.\n3. For the Autism Spectrum Disorder group: Co-occurring other clearly diagnosed neurodevelopmental disorders (such as Rett syndrome, fragile X syndrome, etc.).\n4. Brain structural abnormalities: According to recent cranial MRI and interpretation by neuro-radiology experts, significant brain structural lesions are found (for the patient group, referring to lesions unrelated to Williams Syndrome or autism; for the healthy group, referring to any clinically significant abnormalities).\n5. Major systemic diseases: Presence of diseases with clinical significance as judged by the researchers, which may: affect the interpretation of study results, or endanger the safety of the study participants.","3 Years","12 Years",{"count":195,"type":23},75,"1 Month","Williams Syndrome (WS) is a rare neurodevelopmental disorder, usually caused by microdeletions of approximately 26 genes in the long arm (7q11.23) region of chromosome 7. Children with this syndrome often exhibit distinctive facial features, mild to moderate intellectual disability, impaired spatial cognition, pronounced social extraversion, and relatively reserved language-expression characteristics. Although individuals with WS often demonstrate strong social interest and prosocial behaviors, significant deficiencies in abstract thinking, executive function, and visuospatial ability are frequently observed. At present, treatment for WS mainly focuses on behavioral intervention and educational rehabilitation, and clear molecular or pharmacological treatment methods remain limited. Due to the \"opposite but related\" social-cognitive profile observed in comparison with autism spectrum disorder, in-depth exploration of neural and molecular mechanisms underlying these differences has substantial scientific significance for understanding the biological basis of social-cognitive impairment.",[199,31],"Williams Syndrome",[199,171,201,202],"Neuroimaging","Genetics","2026-03-29",{"date":205,"type":93},"2026-04-03",{"date":180,"type":23},{"date":208,"type":23},"2026-12-01",{"name":210,"class":100},"Qilu Hospital of Shandong University",{"id":212,"slug":213,"hasResults":11,"nctId":214,"briefTitle":215,"officialTitle":216,"acronym":217,"eligibilityCriteria":218,"healthyVolunteers":17,"sex":18,"minAge":108,"maxAge":4,"enrollmentInfo":219,"targetDuration":4,"studyType":24,"phases":221,"briefSummary":222,"conditions":223,"keywords":4,"overallStatus":89,"whyStopped":4,"lastUpdateSubmitDate":230,"lastUpdatePostDateStruct":231,"startDateStruct":233,"completionDateStruct":235,"leadSponsor":237,"locationsCount":101},"100631236","cft-guided-self-help-intervention-parents-of-autistic-children-100631236","NCT07498049","CFT Guided Self-help Intervention: Parents of Autistic Children","Testing a Compassion-focused Guided Self-help Intervention for Parents of Autistic Children - Single Case Series Design","CFT-GSH-PAC","Inclusion Criteria:\n\n* Participants must be a parent who lives with their autistic child. The parent must be aged 18 years and above and their child must be aged between 6 and 17 years old. The parent participant must have good use of the English language to provide informed consent, access the workbook material, listen to the audio tracks, engage verbally in the support telephone calls and change interviews and complete outcome measures. The child must have a formal diagnosis of autism spectrum disorder as confirmed following assessment by a doctor or practitioner psychologist. Participants must be technology-literate and have access to technology to access video calls for screening and check-in calls as needed.\n\nExclusion Criteria:\n\n* Those who are currently receiving psychological or mental health input from professionals, those experiencing thoughts related to self-harm and\u002For suicide and those who are dependent on alcohol or drugs, those with a learning disability or other cognitive impairment will be excluded from this research.",{"count":220,"type":23},8,[26],"This research will aim to test how practical, achievable and effective a brief, guided, self-help compassion focused intervention is for parents of autistic children aged 6-17 years old.\n\nThe demands of parenting can be rewarding but also challenging, and it is known that parents of autistic children experience additional pressures. As a result of this, parents of autistic children may be more likely to experience increased stress, anxiety, low mood and lower quality of life, compared to those parenting children who are not autistic.\n\nThere has been only a small amount of research so far regarding whether interventions that focus on building compassion, would be beneficial to parents of autistic children. The purpose of this study is to test whether a short, self-guided compassion-focused intervention is practical, achievable and effective for parents of autistic children. The intervention is based on Compassion Focused Therapy (CFT) and involves reading workbook material and listening to audio tracks. There will also be some questionnaires to complete and 30-minute weekly support calls with the lead researcher.\n\nThis intervention was adapted previously, from an intervention for parents in general, to be more suitable and focused on the needs of parents of autistic children. This study will be the first time the adapted intervention has been used by parents.\n\nThe intervention will be tested by 6-8 parents and will be about 13 weeks long. We will collect some demographic data at the start of the study, and there will be the opportunity to complete an evaluation questionnaire.",[224,32,31,171,225,226,227,228,229],"Autism Disorders and Maternal Stress","Autism in Children","Parent","Parent Mental Health","Parent Stress","Parent Support","2026-03-23",{"date":232,"type":93},"2026-03-27",{"date":234,"type":23},"2026-04",{"date":236,"type":23},"2027-09",{"name":238,"class":100},"University of Nottingham",{"id":240,"slug":241,"hasResults":11,"nctId":242,"briefTitle":243,"officialTitle":244,"acronym":245,"eligibilityCriteria":246,"healthyVolunteers":17,"sex":18,"minAge":192,"maxAge":247,"enrollmentInfo":248,"targetDuration":4,"studyType":24,"phases":250,"briefSummary":253,"conditions":254,"keywords":256,"overallStatus":175,"whyStopped":4,"lastUpdateSubmitDate":262,"lastUpdatePostDateStruct":263,"startDateStruct":265,"completionDateStruct":267,"leadSponsor":269,"locationsCount":271},"100627577","phase-2-role-of-the-gut-vascular-barrier-and-microbiota-in-autism-spectrum-disorders-100627577","NCT07450443","Role of the Gut Vascular Barrier and Microbiota in Autism Spectrum Disorders","Role of the Gut Vascular Barrier and Microbiota in Autism Spectrum Disorders: Evaluation of Efficacy of Postbiotic-based Nutraceutical Treatment","DSA\u002FGVB","Inclusion Criteria:\n\n* Group 1 and 2:\n\nInclusion criteria\n\n* Diagnosis of ASD according to DSM-5 diagnostic criteria;\n* Clinical neurological evaluation by child neurologist and neuropsychologist with administration of standardized instruments such as Autism Diagnostic Observation Schedule-2 (ADOS-2) and\u002For Autism Diagnostic Interview-Revised (ADI-R) to support diagnosis;\n* Assessment of psychomotor or intellectual development (Griffiths Scales, Wechsler Scales, Leiter Scale)\n* Assessment of the following symptoms in the past three months: constipation, diarrhea, abnormal stool consistency, abnormal stool smell, flatulence, abdominal pain, unexplained daytime irritability, and nighttime awakening, and abdominal tenderness. The degree of gastrointestinal disturbances will be quantified before recruitment using an Italian version of the GI Severity Index. A score of at least 2 in a single item of gastrointestinal symptoms (item 1-6) was required for entry into the symptomatic group.\n* Signed informed consent for analysis of intestinal microbiota and metabolome and administration of nutraceutical therapy with PostbiotiX Comfort ®.\n\nGroup 3 Inclusion criteria\n\n* Males or females aged between 3 and 8 years whit typical development and absence of gastrointestinal symtomps\n* Signed informed consent for analysis of intestinal microbiota and metabolome\n\nExclusion Criteria:\n\nGroup 1 and 2\n\n* Exclusion Criteria\n* Children with syndromic ASD or defined genetic diseases;\n* Subjects with significant health problems requiring surgical treatment or continuous medical; treatment;\n* Severe gastrointestinal problems requiring immediate (life-threatening) treatment;\n* Severely underweight\u002Fmalnourished children;\n* Use of medications that may affect biomarkers assessed, for example: antibiotics and\u002For pre-, probiotics within 1 month prior to enrollment.\n\nGroup 3 exclusion criteria\n\n\\- Participants with gastrointestinal problems requiring immediate (life-threatening) treatment, or with gastrointestinal symptoms such as chronic irregular bowel movements (constipation, diarrhea), encopresis, recurrent abdominal bloating and pain, gastroesophageal reflux and vomiting, or food aversion.","8 Years",{"count":249,"type":23},90,[251,252],"PHASE2","PHASE3","Recent research links gut microbiota alterations to Autism Spectrum Disorders (ASD), a neurobiological condition with multifactorial bases. In some ASD patients, altered gut flora and increased intestinal permeability are observed, influencing the central nervous system's development and function. Chronic gastrointestinal (GI) symptoms are commonly associated with ASD and correlate with its severity. This non-pharmacological interventional clinical study aims to investigate the role of gut microbiota on ASD and the effectiveness of postbiotic-based dietary supplements in children aged 3-8 years old. Gastrointestinal symptoms, behavioral profile and analysis of intestinal metagenomic and metabolomic profiles will be assessed before and after one-month treatment. The results of the study could enhance understanding of non-pharmacological therapeutic approaches in ASD and improve clinical management strategies and the behavioural functioning for children with ASD.",[32,31,255],"Autism Spectrum Disorder (ASD)",[257,258,259,260,261],"Autism Spectrum Disorders (ASD)","Microbiota","Gastrointestinal symptoms","Behaviour regulation","Sensory profile","2026-02-27",{"date":264,"type":93},"2026-03-04",{"date":266,"type":93},"2023-03-21",{"date":268,"type":23},"2027-12",{"name":270,"class":100},"Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta",2,{"id":273,"slug":274,"hasResults":11,"nctId":275,"briefTitle":276,"officialTitle":277,"acronym":4,"eligibilityCriteria":278,"healthyVolunteers":11,"sex":18,"minAge":279,"maxAge":280,"enrollmentInfo":281,"targetDuration":4,"studyType":112,"phases":4,"briefSummary":283,"conditions":284,"keywords":4,"overallStatus":89,"whyStopped":4,"lastUpdateSubmitDate":286,"lastUpdatePostDateStruct":287,"startDateStruct":289,"completionDateStruct":291,"leadSponsor":292,"locationsCount":4},"100625836","follow-up-of-adolescents-with-autism-and-psychotic-symptoms---psychiatric-co-morbidity-and-functional-impairment-100625836","NCT07427810","Follow-up of Adolescents With Autism and Psychotic Symptoms - Psychiatric Co-morbidity and Functional Impairment.","Follow-up of Current Psychotic Symptoms, Level of Function and Psychiatric Co-morbidity Among Adolescents With Autism, 10 Years After Identification of Psychotic Symptoms.","Inclusion Criteria: Age 15-18 at enrollment for the original study, autism spectrum disease, IQ\\>70.\n\nExclusion Criteria: Non.","25 Years","35 Years",{"count":282,"type":23},48,"Purpose: To describe level of function, psychotic and psychiatric symptoms in a 10-year follow up of individuals with autism and psychotic symptoms.\n\nMethod: A case-control study based on a cohort of 48 teenagers with autism established 2013. In the original study, 22 participant reported psychotic symptom in self-evaluation questionnaires design for early detection. We aim to recruit these individuals and controls from the same cohort without psychotic symptoms. Data will be collected from self-rating scales, clinical evaluation including semi-structured interviews and healthcare journals.\n\nThe study is primarily descriptive, with group comparison by non-parametric method.",[31,285],"Schizophrenia and Other Psychotic Disorders","2026-02-17",{"date":288,"type":93},"2026-02-23",{"date":290,"type":23},"2026-02",{"date":268,"type":23},{"name":293,"class":156},"Värmland County Council, Sweden",{"id":295,"slug":296,"hasResults":11,"nctId":297,"briefTitle":298,"officialTitle":299,"acronym":4,"eligibilityCriteria":300,"healthyVolunteers":11,"sex":18,"minAge":301,"maxAge":302,"enrollmentInfo":303,"targetDuration":4,"studyType":24,"phases":305,"briefSummary":306,"conditions":307,"keywords":308,"overallStatus":175,"whyStopped":4,"lastUpdateSubmitDate":313,"lastUpdatePostDateStruct":314,"startDateStruct":316,"completionDateStruct":318,"leadSponsor":320,"locationsCount":101},"100621179","using-virtual-reality-to-improve-emotion-understanding-in-children-with-autism-100621179","NCT07367256","Using Virtual Reality to Improve Emotion Understanding in Children With Autism","Efficacy of a Virtual Reality-Mediated Intervention on Emotion Recognition and Understanding in Children With Autism Spectrum Disorder","Inclusion Criteria:\n\n* Language in sentences\n* Ability to narrate events not present\n* QS\u002FQI\\>80\n\nExclusion Criteria:\n\n* presence of other medical disorders","7 Years","10 Years",{"count":304,"type":23},30,[26],"Autism Spectrum Disorders (ASD) are neurodevelopmental conditions characterized by difficulties in social interaction, communication, and in understanding one's own and others' mental and emotional states. In particular, skills related to the recognition, understanding, and regulation of emotions represent a significant area of vulnerability in children with high-functioning ASD, with important consequences for social and relational functioning.\n\nThe present study aims to evaluate the effectiveness of an intervention protocol designed to enhance socio-emotional understanding, with a specific focus on the recognition of basic and complex emotions, the expansion of emotional vocabulary, the association between situations, thoughts, and emotions, and the differentiation between thoughts and emotions. Furthermore, the study seeks to investigate the role of immersive technology (Oculus) as a potential facilitator of emotional learning compared to a traditional intervention approach. The sample will consist of children with a diagnosis of high-functioning ASD, aged between 7 and 10 years, with sentence-level language abilities, the capacity to narrate non-present events, and an intellectual quotient above 80 (assessed using the Griffiths Scales or the WISC-IV). Participants will be divided into two groups: an experimental group (OCULUS), which will receive the intervention mediated by the use of Oculus technology, and a control group which will undergo the same protocol without technological support.",[32,31],[143,309,310,311,312],"children","emotional skills","virtual reality","emotional recognition","2026-01-16",{"date":315,"type":93},"2026-01-26",{"date":317,"type":23},"2026-02-02",{"date":319,"type":23},"2026-07-31",{"name":321,"class":100},"Istituto per la Ricerca e l'Innovazione Biomedica",{"id":323,"slug":324,"hasResults":11,"nctId":325,"briefTitle":326,"officialTitle":327,"acronym":328,"eligibilityCriteria":329,"healthyVolunteers":17,"sex":18,"minAge":330,"maxAge":108,"enrollmentInfo":331,"targetDuration":4,"studyType":24,"phases":332,"briefSummary":333,"conditions":334,"keywords":336,"overallStatus":89,"whyStopped":4,"lastUpdateSubmitDate":343,"lastUpdatePostDateStruct":344,"startDateStruct":346,"completionDateStruct":347,"leadSponsor":349,"locationsCount":101},"100619175","how-virtual-reality-can-help-neurodivergent-children-improve-their-attention-100619175","NCT07341204","How Virtual Reality Can Help Neurodivergent Children Improve Their Attention","Improvement of Sustained Attention Through Immersive Virtual Reality in Neurodivergent Children","Attend-VR","Inclusion Criteria:\n\n* Clinical diagnosis of ASD, ADHD, SLD, or DCD confirmed by a licensed clinician or documented in medical\u002Feducational records (DSM-5 or equivalent).\n* Parent\u002Fguardian consent and participant assent (age-appropriate).\n* Ability to follow simple verbal instructions and to participate in 25-minute VR sessions twice weekly for 6 weeks.\n* Stable medication regimen for attention- or behavior-related medications for ≥4 weeks prior to baseline (or not taking such medications).\n* Visual and auditory ability adequate for VR tasks (with or without usual corrective lenses\u002Fhearing aids).\n* Availability to attend all scheduled sessions at the clinical site across the 6-week period.\n\nExclusion Criteria:\n\n* History of photosensitive epilepsy or any uncontrolled seizure disorder.\n* Severe intellectual disability or severe communication impairment that prevents understanding\u002Fparticipation (e.g., non-responsive to simple commands required by the VR tasks).\n* Severe visual, auditory, or motor impairment that prevents safe or functional use of the VR system (e.g., inability to hold controllers or view the headset even with correction).\n* Recent (within 6 months) significant brain injury or neurosurgery. Significant history of motion sickness, severe vestibular disorder, or prior intolerance to immersive VR.\n* Any medical or implanted device contraindicated for VR\u002Fheadset use (if applicable).","9 Years",{"count":167,"type":23},[26],"The goal of this study is to determine whether playing a virtual reality (VR) game can help neurodivergent children pay attention for extended periods. The study includes children ages 9 to 18 who have autism, ADHD, learning differences, or movement coordination challenges. The program lasts for 6 weeks. During this period, children will play a VR game twice per week, with each session lasting 25 minutes.",[32,31,33,335],"Attention Deficit Disorder",[337,338,339,340,341,342],"attention","impulsivity","distractability","focus","VR","Immersive Virtual Reality","2026-01-06",{"date":345,"type":93},"2026-01-14",{"date":317,"type":23},{"date":348,"type":23},"2026-04-06",{"name":350,"class":100},"New York Institute of Technology",{"id":352,"slug":353,"hasResults":11,"nctId":354,"briefTitle":355,"officialTitle":356,"acronym":357,"eligibilityCriteria":358,"healthyVolunteers":11,"sex":18,"minAge":4,"maxAge":359,"enrollmentInfo":360,"targetDuration":4,"studyType":24,"phases":361,"briefSummary":362,"conditions":363,"keywords":367,"overallStatus":175,"whyStopped":4,"lastUpdateSubmitDate":374,"lastUpdatePostDateStruct":375,"startDateStruct":377,"completionDateStruct":379,"leadSponsor":381,"locationsCount":101},"100616164","impact-and-determinants-of-success-of-a-mobile-multidisciplinary-intervention-system-specialized-in-pain-management-for-patients-with-moderate-to-severe-intellectual-development-disorder-isolated-or-associated-with-an-asd-or-multiple-disability-100616164","NCT07302048","Impact and Determinants of Success of a Mobile Multidisciplinary Intervention System Specialized in Pain Management for Patients With Moderate to Severe Intellectual Development Disorder, Isolated or Associated With an ASD or Multiple Disability","Impact and Determinants of Success of a Mobile Multidisciplinary Intervention System Specialized in Pain Management for Patients With Moderate to Severe Intellectual Development Disorder, Isolated or Associated With an ASD or Multiple Disability - MoDIDol","MoDIDol","Inclusion Criteria:\n\n* Aged from birth up to 24 years inclusive (i.e., under 25 years old)\n* Medical diagnosis of intellectual disability (ID), isolated or associated with autism spectrum disorder (ASD), developmental disorder (DD), or profound multiple disabilities, based on international classification systems (ICD-11 or DSM-5)\n* Confirmed probable or definite pain diagnosis, as validated by the MoDIDol team\n* PGIC score ≥ 3\n* Living in or receiving care in the departments of Finistère, Côtes-d'Armor, or Morbihan\n* Written informed consent provided by parents, legal guardians, or holders of parental authority, authorizing data collection for research and publication purposes\n* Affiliated with or benefiting from a French national health insurance scheme\n\nExclusion Criteria:\n\n* More than three places of residence and\u002For care settings\n* Parents or legal guardians who do not have sufficient language or comprehension skills to provide informed consent or complete study questionnaires","24 Years",{"count":111,"type":23},[26],"Pain is described by patients with a Neurodevelopmental Disorder (NDD), including Autism Spectrum Disorder (ASD), Intellectual Development Disorder (IDD) or multiple disabilities, and the family as one of the main associated disorders; its management is also one of the main concerns of families and professionals. At present, there is no validated and tested pain management system in populations facing complex pain situations. In response to the lack of a pain management services, a multi-disciplinary mobile team was set up in September 2022 at the Brest University Hospital (Mobile Pain Handicap Team Intellectual Disability 0-25 years; MoDIDol). This team offers a specific protocol for the assessment and management of pain that takes into account the social and family environment, the living context and the clinical characteristics of patients (children, adolescents and young adults (0-25 years) with IDD, ASD or multiple disabilities). The team includes at least one paediatrician specialising in the assessment and treatment of pain and a nurse, and travels to patients' usual living environments.",[31,364,365,366],"Multiple Disabilities","Pain","Intellectual Developmental Disorder",[365,368,369,370,371,171,372,373],"Children","Adolescents","young adults","Intellectual Developmental Disability","multiple disabilities","mobile team","2025-12-11",{"date":376,"type":93},"2025-12-24",{"date":378,"type":93},"2025-10-14",{"date":380,"type":23},"2028-04-20",{"name":382,"class":100},"University Hospital, Brest",{"id":384,"slug":385,"hasResults":11,"nctId":386,"briefTitle":387,"officialTitle":388,"acronym":389,"eligibilityCriteria":390,"healthyVolunteers":11,"sex":18,"minAge":391,"maxAge":279,"enrollmentInfo":392,"targetDuration":4,"studyType":24,"phases":394,"briefSummary":395,"conditions":396,"keywords":397,"overallStatus":89,"whyStopped":4,"lastUpdateSubmitDate":401,"lastUpdatePostDateStruct":402,"startDateStruct":404,"completionDateStruct":406,"leadSponsor":408,"locationsCount":101},"100612773","phase-3-nti164-in-autism-spectrum-disorder-100612773","NCT07257939","NTI164 in Autism Spectrum Disorder","A Phase III Double-blind, Randomised, Placebo-controlled Study Investigating the Efficacy and Safety of NTI164 in Children and Young Adults With Autism Spectrum Disorder","HarmonyPlus","Inclusion Criteria:\n\n1. Participant is aged 6 years to 25 years (inclusive).\n2. Participant is at a healthy weight at the discretion of the Principal Investigator.\n3. Written informed consent from parent or legal guardian according to the local law.\n4. Participants can comply with trial requirements.\n5. According the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5) criteria the participant has a diagnosis of Level II or III ASD confirmed by a validated assessment tool.\n6. All treatments including medications and therapies for ASD related symptoms must have been stable for 12 weeks before enrolment and for the duration of the trial wherever possible.\n7. Participants must be able to swallow liquid.\n8. Consent giver must be able to understand the requirements of the study.\n\nExclusion Criteria:\n\n1. Current diagnosis of bipolar disorder, psychosis, schizophrenia, schizoaffective disorder, or active major depression.\n2. Has a diagnosis other than ASD that dominates the clinical presentation (e.g., ADHD).\n3. Has a degenerative condition.\n4. Changes in anticonvulsive therapy within the last 12 weeks.\n5. Taking omeprazole, lansoprazole, tolbutamide, warfarin, sirolimus, everolimus, temsirolimus, tacrolimus, clobazam, repaglinide, pioglitazone, rosiglitazone, montelukast, bupropion, or efavirenz.\n6. Currently using or has used recreational or medicinal cannabis, cannabinoid-based medications (including Sativex®, or Epidiolex®) within the 12 weeks prior to screening and is unwilling to abstain for the duration of the trial.\n7. Participant has any known or suspected hypersensitivity to cannabinoids or any of the excipients.\n8. Participant has moderately impaired hepatic function at screening, defined as serum alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \\> 2 × upper limit of normal (ULN) or total bilirubin (TBL) \\> 2 × ULN. This criterion can only be confirmed once the laboratory results are available; participants enrolled into the trial who are later found to meet this criterion must be screen-failed.\n9. Participant is male and fertile (i.e., after puberty unless permanently sterile by bilateral orchidectomy) unless willing to ensure that they use male contraception (condom) or remain sexually abstinent during the trial and for 12 weeks thereafter.\n10. Participant is female and with childbearing potential (i.e., following menarche and until becoming postmenopausal for ≥ 12 consecutive months unless permanently sterile by hysterectomy, bilateral salpingectomy, or bilateral oophorectomy) unless willing to ensure that they use a highly effective method of birth control (e.g., hormonal contraception, intrauterine device\u002Fhormone-releasing system, bilateral tubal occlusion, vasectomised partner, sexual abstinence) during the trial and for 12 weeks thereafter.\n11. Female participant who is pregnant (positive pregnancy test), lactating or planning pregnancy during the course of the trial or within 12 weeks thereafter.\n12. Participant had brain surgery or traumatic brain injury within 1 year of screening.\n13. Participant has any other significant disease or disorder which, in the opinion of the Investigator, may either put the participant, other participants, or site staff at risk because of participation in the trial, may influence the result of the trial, or may affect the participant's ability to take part in the trial.\n14. Any abnormalities identified following a physical examination of the participant that, in the opinion of the Investigator, would jeopardise the safety of the participant if they took part in the trial.\n15. Any history of suicidal behaviour (lifelong) or any suicidal ideation of type 4 or 5 on the Columbia-Suicide Severity Rating Scale (C-SSRS) in the last 12 weeks or at screening or randomisation.\n16. Participant has donated blood during the past 12 weeks and is unwilling to abstain from donation of blood during the trial.\n17. Participant has any known or suspected history of alcohol or substance abuse or positive drugs of abuse test at screening (not justified by a known concurrent medication).\n18. Participant has previously been enrolled into this trial.\n19. Participant has plans to travel outside their country of residence during the trial, unless the participant has confirmation that the product is permitted in the destination country\u002Fstate.","6 Years",{"count":393,"type":23},98,[252],"This is a double-blind, randomised, placebo-controlled study investigating the efficacy of a full-spectrum medicinal cannabis plant extract on core and associated ASD symptoms over placebo. Participants will be randomly allocated to either NTI164 or placebo at a 1:1 ratio and blood samples will be collected and surveys completed at baseline and Week 16. This study will expand efficacy and safety data of NTI164 and provide additional mechanism of action data of NTI164 in this patient cohort.",[32,171,31],[398,399,400],"Cannabis","NTI164","Autism spectrum disorder","2025-11-26",{"date":403,"type":93},"2025-12-02",{"date":405,"type":23},"2026-07-01",{"date":407,"type":23},"2030-07-01",{"name":409,"class":410},"Fenix Innovation Group","INDUSTRY",{"id":412,"slug":413,"hasResults":11,"nctId":414,"briefTitle":415,"officialTitle":416,"acronym":4,"eligibilityCriteria":417,"healthyVolunteers":11,"sex":18,"minAge":108,"maxAge":418,"enrollmentInfo":419,"targetDuration":4,"studyType":24,"phases":421,"briefSummary":422,"conditions":423,"keywords":4,"overallStatus":89,"whyStopped":4,"lastUpdateSubmitDate":424,"lastUpdatePostDateStruct":425,"startDateStruct":427,"completionDateStruct":429,"leadSponsor":431,"locationsCount":101},"100602035","the-intervention-of-lactobacillus-plantarum-probiotics-in-adult-autistic-spectrum-disorders-100602035","NCT07118267","The Intervention of Lactobacillus Plantarum Probiotics in Adult Autistic Spectrum Disorders","The Intervention of Lactobacillus Plantarum Probiotics in Adult Patients With Autistic Spectrum Disorders Investigating Associations of Microbiota, Inflammation, Social Interactions, Quality of Life, and Gait Analysis: A Qualitative and Quantitative Mixed & A Double-blind Randomized Controlled Trial","Inclusion Criteria:\n\n* Those who have been diagnosed with autistic spectrum disorder aged 18\\~50 years old\n* Those whose primary contacts or caregiver (including family members or teachers) are willing to participate\n* Those whose primary contacts or caregivers can understand Mandarin and can answer relevant questions or questionnaires.\n\nExclusion Criteria:\n\n* Have taken antibiotics or are receiving antibiotic treatment within one month.\n* Have used probiotic products in powder, capsule or tablet form within two weeks (excluding yogurt, Yakult and other related foods).\n* Patients who have undergone hepatobiliary gastrointestinal surgery (except for colorectal polypectomy and appendectomy).\n* Past or current patients with inflammatory bowel disease.\n* Those with a history of cancer.\n* Those who are allergic to lactic acid bacteria products.\n* Those who are receiving parenteral nutrition.\n* Those who are evaluated by the principal investigator to be unsuitable to participate in the research.","50 Years",{"count":420,"type":23},12,[26],"This is a qualitative and quantitative mixed-methods, open-label study, will involve 12 participants and their caregivers. Participants will also undergo blood exams and gait analysis, while caregivers will complete qualitative interviews and quantitative questionnaires on autistic symptoms, stress, anxiety, and quality of life. After the baseline assessments, participants will receive Lactobacillus plantarum for 8 weeks, followed by further evaluations at end point.",[31],"2025-08-05",{"date":426,"type":93},"2025-08-12",{"date":428,"type":23},"2025-09-01",{"date":430,"type":23},"2026-08-31",{"name":432,"class":100},"Mackay Memorial Hospital",{"id":434,"slug":435,"hasResults":11,"nctId":436,"briefTitle":437,"officialTitle":437,"acronym":438,"eligibilityCriteria":439,"healthyVolunteers":11,"sex":18,"minAge":440,"maxAge":165,"enrollmentInfo":441,"targetDuration":4,"studyType":24,"phases":443,"briefSummary":444,"conditions":445,"keywords":448,"overallStatus":175,"whyStopped":4,"lastUpdateSubmitDate":456,"lastUpdatePostDateStruct":457,"startDateStruct":459,"completionDateStruct":461,"leadSponsor":462,"locationsCount":101},"100600748","using-technologies-to-promote-healthy-lifestyles-in-adolescents-with-intellectual-disabilities-100600748","NCT07101523","Using Technologies to Promote HEalthy Lifestyles in Adolescents With Intellectual Disabilities","IDHEAPP","Inclusion Criteria:\n\n* Diagnosis of intellectual disability\n* Being able to follow basic instructions\n* Age between 4-30 years old\n\nExclusion Criteria:\n\n* presence of severe sensory or motor impairments\n* medical conditions that contraindicated moderate physical activity\n* unable to access an smartphone during the intervention","4 Years",{"count":442,"type":23},60,[26],"IDHEApp will implement various educational technology tools and work with the families, teachers and caregivers to increase physical activity (PA) and improve healthy eating. Due to the current COVID-19 pandemic restrictions, the use of innovative digital technology can contribute not just to distance learning but also to support families and students in remote. However, both healthy habits and technologies are insufficiently addressed in the population with IDD. These needs are in line with the following objectives of the Erasmus+ programme: a) Inclusion and diversity in all fields of education, training, youth and sport; b) Addressing digital transformation through development of digital readiness, resilience and capacity, and c) Encouraging the participation in sport and physical activity.\n\nEducators will find innovative possibilities and the right instruments that will enable them to fulfil their potential through innovative online education \\& learning \\& training skills module for lifestyle promotion and others available on the app. Furthermore, mentors and others health professionals (e.g., nursing etc.) will be equipped with knowledge and skills on how to use the app to teach practical skills for PA enhancement in an evidence-based way. Consequently, this project will contribute to \\[specific objectives - SO\\]:\n\n\\- Raise awareness of the importance of healthy and active living among young Europeans with intellectual disabilities.\n\nDifferent workshops and bigger events (i.e., international conference), together with the involvement of numerous participants from the institutions of this consortium will be ensured. Further, a sensitized community will participate through the social networks and the website itself, in the proposed activities.\n\n\\- Provide digital resources and tools to the partner entities of the exchange to improve lifestyle of young people with intellectual disabilities.\n\nBest Practices to provide high quality, inclusive digital health education with the best educational technology tools and methodology. A website, a mobile app and different electronic guidelines will be delivered.\n\n\\- Analyze the current state of use and acceptance of technologies as support in the management of health in adolescent with intellectual disabilities.",[446,447,31],"Intellectual Disabilities (F70-F79)","Down Syndrome (DS)",[449,450,451,452,453,454,455],"Intellectual Disabilities","Physical Activity","Sedentary Behavior","mHealth","Health Behavior Change","Health Promotion","Lifestyle Intervention","2025-08-02",{"date":458,"type":93},"2025-08-07",{"date":460,"type":93},"2024-01-01",{"date":428,"type":23},{"name":463,"class":100},"University of Seville",{"id":465,"slug":466,"hasResults":11,"nctId":467,"briefTitle":468,"officialTitle":468,"acronym":469,"eligibilityCriteria":470,"healthyVolunteers":17,"sex":18,"minAge":136,"maxAge":4,"enrollmentInfo":471,"targetDuration":4,"studyType":24,"phases":473,"briefSummary":474,"conditions":475,"keywords":4,"overallStatus":175,"whyStopped":4,"lastUpdateSubmitDate":482,"lastUpdatePostDateStruct":483,"startDateStruct":485,"completionDateStruct":487,"leadSponsor":489,"locationsCount":101},"100597159","rural-autistic-individuals---supporting-expression-100597159","NCT07054866","Rural Autistic Individuals - Supporting Expression","RAISE","Inclusion Criteria:\n\n* 1.1 Confirmed (preferably) or suspected diagnosis of ASD (autism spectrum disorder), or a receptive language impairment (i.e., difficulties with comprehension, Developmental Language Disorder), or both. Additional diagnoses, including ADHD (Attention Deficit and Hyperactivity Disorder), are acceptable. Siblings and cousins of these individuals are also welcome.\n\nOR 1.2 No diagnoses of ASD or DLD for unrelated control typically-developing participants.\n\n2\\. Normal hearing and normal vision (or corrected to normal with glasses or contacts).\n\n3\\. Ages 2+. 4. English as the dominant language of caregivers. 5. Caregivers who self-identify as living in a rural area. 6. The ability to verbally or physically respond is optional.\n\nExclusion Criteria:\n\n* 1\\. Poor hearing. 2. Inborn or acquired brain damage.",{"count":472,"type":23},50,[26],"This research study investigates how hand gestures can support language comprehension and communication skills of hearing speaking, non-speaking, and\u002For minimally verbal individuals with Autism Spectrum Disorders (ASD), who are especially disadvantaged by the lack of accessible services in their rural communities. Individuals with other cognitive profiles, including Developmental Language Disorder (DLD), ADHD, Dyslexia, and others are welcome too. The study uses methods of eye tracking and recording of brain activity to understand how hand gestures adapted from signs from American Sign Language, such as \\[cry\\], can promote successful understanding of words like \"cry\". The overarching goal is to help families effectively utilize gestures to support communication with their children.",[31,476,34,477,478,368,201,479,480,481],"Language Development Disorders","Typical Development","Rural Health","Eye Tracking","EEG","fNIRS","2025-07-07",{"date":484,"type":93},"2025-07-10",{"date":486,"type":23},"2025-07",{"date":488,"type":23},"2027-07",{"name":490,"class":100},"Montana State University"]